{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH1-mutant+Glioma",
    "query": {
      "condition": "IDH1-mutant Glioma"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 14,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=IDH1-mutant+Glioma&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-25T19:53:49.136Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07629089",
      "title": "VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "Vorasidenib",
          "type": "DRUG"
        },
        {
          "name": "Lomustine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Megan Mantica",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-06-30",
      "completion_date": "2035-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-05",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07629089"
    },
    {
      "nct_id": "NCT05484622",
      "title": "Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Astrocytoma",
        "Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "Vorasidenib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-01-20",
      "completion_date": "2027-08-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05484622"
    },
    {
      "nct_id": "NCT02977689",
      "title": "Trial of IDH305 in IDH1 Mutant Grade II or III Glioma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "IDH305",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-04",
      "completion_date": "2020-04",
      "has_results": false,
      "last_update_posted_date": "2017-12-20",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02977689"
    },
    {
      "nct_id": "NCT05609994",
      "title": "ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Low Grade Glioma of Brain"
      ],
      "interventions": [
        {
          "name": "PEPIDH1M vaccine + vorasidenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Katy Peters, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-07-15",
      "completion_date": "2029-08",
      "has_results": false,
      "last_update_posted_date": "2025-07-18",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05609994"
    },
    {
      "nct_id": "NCT03749187",
      "title": "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "IDH1 Gene Mutation",
        "IDH2 Gene Mutation",
        "Low Grade Glioma",
        "Malignant Glioma",
        "Recurrent Glioblastoma",
        "Recurrent WHO Grade II Glioma",
        "Recurrent WHO Grade III Glioma",
        "WHO Grade II Glioma",
        "WHO Grade III Glioma"
      ],
      "interventions": [
        {
          "name": "PARP Inhibitor BGB-290",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "13 Years to 39 Years"
      },
      "enrollment_count": 78,
      "start_date": "2019-04-03",
      "completion_date": "2029-07-30",
      "has_results": false,
      "last_update_posted_date": "2026-03-13",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03749187"
    },
    {
      "nct_id": "NCT03212274",
      "title": "Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Glioblastoma",
        "Recurrent Cholangiocarcinoma",
        "Recurrent Glioma",
        "Recurrent Malignant Solid Neoplasm",
        "WHO Grade 2 Glioma",
        "WHO Grade 3 Glioma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 89,
      "start_date": "2019-01-30",
      "completion_date": "2026-07-28",
      "has_results": true,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 51,
      "location_summary": "Costa Mesa, California • Los Angeles, California • Newport Beach, California + 36 more",
      "locations": [
        {
          "city": "Costa Mesa",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03212274"
    },
    {
      "nct_id": "NCT04056910",
      "title": "Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "IDH1 Mutation",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "ivosidenib and nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jason J. Luke, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-09-20",
      "completion_date": "2023-11-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04056910"
    },
    {
      "nct_id": "NCT06478212",
      "title": "Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "IDH1-mutant Glioma",
        "IDH2-mutant Glioma"
      ],
      "interventions": [
        {
          "name": "Vorasidenib",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2025-01-22",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Miami, Florida • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06478212"
    },
    {
      "nct_id": "NCT06161974",
      "title": "Study of Olutasidenib and Temozolomide in HGG",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Grade Glioma",
        "Astrocytoma",
        "Astrocytoma, Grade III",
        "Astrocytoma, Grade IV",
        "Diffuse Intrinsic Pontine Glioma",
        "WHO Grade III Glioma",
        "WHO Grade IV Glioma",
        "Metastatic Brain Tumor",
        "Diffuse Midline Glioma, H3 K27M-Mutant",
        "Thalamus Tumor",
        "Spinal Tumor",
        "IDH1 Mutation",
        "IDH1 R132",
        "IDH1 R132C",
        "IDH1 R132H",
        "IDH1 R132S",
        "IDH1 R132G",
        "IDH1 R132L",
        "Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "Olutasidenib + TMZ",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "12 Years to 39 Years"
      },
      "enrollment_count": 60,
      "start_date": "2025-02-01",
      "completion_date": "2035-06",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 11,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 8 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161974"
    },
    {
      "nct_id": "NCT07219199",
      "title": "Residual IDH1-Mutant Tumor Cell Quantification Study",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "UR-ddPCR",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 105,
      "start_date": "2025-12",
      "completion_date": "2030-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-21",
      "last_synced_at": "2026-06-25T19:53:49.136Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07219199"
    }
  ]
}